Metzger Michael A
Chief Executive Officer at SNDX; Director at CELL THERAPEUTICS INC
- Sold, on record
- $16.6M
- Dollars the filings state
- Form 4 sales
- 25
- Latest Jul 8, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- SNDXSyndax Pharmaceuticals IncChief Executive Officer
- CELL THERAPEUTICS INCDirector
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- SNDX787,406 shares
- CELL THERAPEUTICS INC203,121 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale SNDXNo planFeb 10, 2025 2025
Sold 13,288 shares at $15.50 ($206k)
Metzger Michael A, Chief Executive Officer
No 10b5-1 planSold 4.2% of holdings ($4.9M position)300,121 shares leftFirst sale on recordFiling
- 2 Form 4 sale SNDXRoutineMar 4, 2025 +22 days
Sold 7,814 shares at $15.05 ($118k)
Metzger Michael A, Chief Executive Officer
10b5-1 planSold 2.5% of holdings ($4.6M position)300,121 shares leftFiling
- 3 Form 4 sale SNDXNo planJul 16, 2025 +134 days
Sold 7,534 shares at $9.29 ($70k)
Metzger Michael A, Chief Executive Officer
No 10b5-1 planSold 2.5% of holdings ($2.8M position)298,661 shares leftFiling
- 4 Form 4 sale SNDXUnusualSep 8, 2025 +54 days
Sold 157,307 shares at $16.41 ($2.6M)
Metzger Michael A, Chief Executive Officer
10b5-1 planSold 34.5% of holdings ($7.5M position)298,661 shares left20.1x usual sizeFiling
- 5 Form 4 sale SNDXNo planFeb 6, 2026 +151 days
Sold 7,412 shares at $20.62 ($153k)
Metzger Michael A, Chief Executive Officer
No 10b5-1 planSold 1.4% of holdings ($10.6M position)508,849 shares left0.7x usual sizeFiling
- 6 Form 4 sale SNDXNo planFeb 9, 2026 +3 days
Sold 17,159 shares at $21.03 ($361k)
Metzger Michael A, Chief Executive Officer
No 10b5-1 planSold 3.4% of holdings ($10.7M position)491,690 shares left2.2x usual sizeFiling
- 7 Form 4 sale SNDXNo planJun 1, 2026 +112 days
Sold 6,847 shares at $18.99 ($130k)
Metzger Michael A, Chief Executive Officer
No 10b5-1 planSold 1.4% of holdings ($9.3M position)484,843 shares left0.6x usual sizeFiling
- 8 Form 4 sale SNDXUnusualJul 8, 2026 +37 days
Sold 32,375 shares at $24.24 ($785k)
Metzger Michael A, Chief Executive Officer
10b5-1 planSold 6.3% of holdings ($12.5M position)484,843 shares left4.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (25)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Jul 9, 2026 | SNDX | Chief Executive Officer | Form 4 sale | 32,375 | $785k | 6.3% | Unusual | SEC |
| Jun 1, 2026 | Jun 2, 2026 | SNDX | Chief Executive Officer | Form 4 sale | 6,847 | $130k | 1.4% | No plan | SEC |
| Feb 9, 2026 | Feb 10, 2026 | SNDX | Chief Executive Officer | Form 4 sale | 17,159 | $361k | 3.4% | No plan | SEC |
| Feb 6, 2026 | Feb 6, 2026 | SNDX | Chief Executive Officer | Form 4 sale | 7,412 | $153k | 1.4% | No plan | SEC |
| Sep 8, 2025 | Sep 8, 2025 | SNDX | Chief Executive Officer | Form 4 sale | 157,307 | $2.6M | 34.5% | Unusual | SEC |
| Jul 16, 2025 | Jul 18, 2025 | SNDX | Chief Executive Officer | Form 4 sale | 7,534 | $70k | 2.5% | No plan | SEC |
| Mar 4, 2025 | Mar 6, 2025 | SNDX | Chief Executive Officer | Form 4 sale | 7,814 | $118k | 2.5% | Routine | SEC |
| Feb 10, 2025 | Feb 12, 2025 | SNDX | Chief Executive Officer | Form 4 sale | 13,288 | $206k | 4.2% | No plan | SEC |
| Feb 6, 2023 | Feb 8, 2023 | SNDX | Chief Executive Officer | Form 4 sale | 5,959 | $165k | 25.2% | Unusual | SEC |
| Nov 8, 2022 | Nov 10, 2022 | CELL THERAPEUTICS INC | Director | Form 4 sale | 91,500 | $511k | 100.0% | Unusual | SEC |
| Oct 6, 2022 | Oct 7, 2022 | SNDX | Chief Executive Officer | Form 4 sale | 16,231 | $410k | 47.9% | Unusual | SEC |
| Oct 4, 2022 | Oct 4, 2022 | SNDX | Chief Executive Officer | Form 4 sale | 33,769 | $845k | 65.7% | Unusual | SEC |
| Jul 25, 2022 | Jul 27, 2022 | SNDX | Chief Executive Officer | Form 4 sale | 31,602 | $666k | 64.2% | Unusual | SEC |
| Jul 7, 2022 | Jul 11, 2022 | CELL THERAPEUTICS INC | Director | Form 4 sale | 20,121 | $131k | 100.0% | Unusual | SEC |
| Jul 7, 2022 | Jul 8, 2022 | SNDX | Chief Executive Officer | Form 4 sale | 15,109 | $318k | 46.1% | Unusual | SEC |
| Jul 5, 2022 | Jul 7, 2022 | CELL THERAPEUTICS INC | Director | Form 4 sale | 91,500 | $556k | 82.0% | Unusual | SEC |
| Dec 20, 2021 | Dec 20, 2021 | SNDX | President and COO | Form 4 sale | 85,391 | $1.7M | 82.9% | Unusual | SEC |
| Dec 13, 2021 | Dec 15, 2021 | SNDX | President and COO | Form 4 sale | 36,609 | $697k | 67.5% | Unusual | SEC |
| Oct 26, 2021 | Oct 27, 2021 | SNDX | President and COO | Form 4 sale | 61,000 | $1.2M | 77.5% | Unusual | SEC |
| Sep 27, 2021 | Sep 28, 2021 | SNDX | President and COO | Form 4 sale | 24,437 | $477k | 58.1% | Unusual | SEC |
| Sep 22, 2021 | Sep 22, 2021 | SNDX | President and COO | Form 4 sale | 36,563 | $703k | 67.4% | Unusual | SEC |
| Sep 14, 2021 | Sep 15, 2021 | SNDX | President and COO | Form 4 sale | 61,000 | $1.2M | 77.5% | Unusual | SEC |
| Feb 1, 2021 | Feb 3, 2021 | SNDX | President and COO | Form 4 sale | 15,000 | $303k | 45.9% | Unusual | SEC |
| Dec 1, 2020 | Dec 3, 2020 | SNDX | President and COO | Form 4 sale | 15,000 | $345k | 45.9% | Unusual | SEC |
| Nov 4, 2020 | Nov 6, 2020 | SNDX | President and COO | Form 4 sale | 100,000 | $2M | 85.0% | Unusual | SEC |